Millat Gilles, Chanavat Valérie, Rousson Robert
Laboratoire de Cardiogénétique Moléculaire, Centre de Biologie et Pathologie Est, Hospices Civils de Lyon, Lyon, 69677, Bron Cedex, France,
Mol Diagn Ther. 2014 Oct;18(5):533-9. doi: 10.1007/s40291-014-0099-y.
Inherited long QT syndrome (LQTS) is a cardiac channelopathy associated with a high risk of sudden death. The prevalence has been estimated at close to 1:2,000. Due to large cohorts to investigate and high rate of private mutations, mutational screening must be performed using an extremely sensitive and specific detection method. Mutational screening is crucial as this may have implications for therapy and management of LQTS patients.
Next-generation sequencing (NGS) workflow based on a custom AmpliSeq™ panel was designed for sequencing the five most prevalent cardiomyopathy-causing genes (KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2) on Ion PGM™ Sequencer. A cohort of 30 previously studied patients was screened to evaluate this strategy in terms of sensitivity, specificity, practicability, and cost. In silico analysis was performed using NextGENe(®) software.
Our AmpliSeq™ custom panel allowed us to explore 86 % of targeted sequences efficiently. Using adjusted alignment settings, all genetic variants (40 substitutions, 17 indels) present in covered regions and previously detected by high-resolution melt (HRM)/sequencing were readily identified. Uncovered targeted regions, which were mainly located in KCNH2, were further analyzed by HRM/sequencing strategy. Complete molecular investigation was performed faster and cheaper than with previously used mutation detection methods.
Finally, these results suggested that our new NGS approach based on AmpliSeq™ libraries and Ion PGM™ sequencing is a highly efficient, fast, and cheap high-throughput mutation detection method that is ready to be deployed in clinical laboratories. This method will allow fast identification of LQTS mutations that will have further implications for therapeutics.
遗传性长QT综合征(LQTS)是一种与猝死高风险相关的心脏离子通道病。据估计,其患病率接近1:2000。由于需要研究的队列庞大且存在大量私人突变,必须使用极其灵敏和特异的检测方法进行突变筛查。突变筛查至关重要,因为这可能对LQTS患者的治疗和管理产生影响。
基于定制的AmpliSeq™ 芯片设计了新一代测序(NGS)工作流程,用于在Ion PGM™ 测序仪上对五个最常见的致心肌病基因(KCNQ1、KCNH2、SCN5A、KCNE1、KCNE2)进行测序。对30例先前研究过的患者组成的队列进行筛查,以评估该策略在敏感性、特异性、实用性和成本方面的表现。使用NextGENe® 软件进行计算机分析。
我们的AmpliSeq™ 定制芯片使我们能够高效地探索86%的目标序列。使用调整后的比对设置,覆盖区域内所有先前通过高分辨率熔解曲线分析(HRM)/测序检测到的基因变异(40个替换、17个插入/缺失)都能轻松识别。未覆盖的目标区域主要位于KCNH2基因,通过HRM/测序策略进一步分析。与先前使用的突变检测方法相比,完整的分子研究完成得更快且成本更低。
最后,这些结果表明,我们基于AmpliSeq™ 文库和Ion PGM™ 测序的新NGS方法是一种高效、快速且廉价的高通量突变检测方法,可随时应用于临床实验室。该方法将有助于快速识别LQTS突变,这将对治疗产生进一步影响。